Rifaximin
3 NDCs across 1 manufacturer|0 Generic,3 Brand
Rifaximin is used to treat diarrhea and irritable bowel syndrome, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on May 25, 2004, and the first generic was approved Mar 19, 2026. FDA's Orange Book lists 2 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $1.2 billion on Rifaximin across 417,000 claims for 105,000 beneficiaries.
Rifaximin is available as 3 NDCs from 1 manufacturer (0 generic, 3 brand), with NADAC prices from $10.72 to $55.28 per EA — the most expensive product costs about 5.2× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
3
0G / 3B
Manufacturers
1
competing in market
Price Spread
$10.72 – $55.28
per EA
7d Activity
avg +0.0% WoW · of 3 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Salix Pharmaceuticals Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Rifamycin Antibacterial class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing RIFAXIMIN
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
XIFAXAN 550 MG TABLET | $55.2802 per EA | — |
XIFAXAN 550 MG TABLET | $55.2802 per EA | — |
XIFAXAN 200 MG TABLET | $10.7162 per EA | — |
Frequently Asked Questions
What is Rifaximin used to treat?
Rifaximin is used to treat diarrhea and irritable bowel syndrome, per the National Library of Medicine's MED-RT classification.
When did Rifaximin become available as a generic?
FDA approved the first generic Rifaximin (ANDA) on Mar 19, 2026. The Orange Book currently lists 2 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Rifaximin?
In 2024, Medicare Part D spent $1.2 billion on Rifaximin across 417,000 claims for 105,000 beneficiaries.
How many Rifaximin products are on the market?
The Rifaximin drug market contains 3 NDCs from 1 manufacturer — 0 generic and 3 brand products.
What is the price range for Rifaximin?
NADAC reference prices for Rifaximin range from $10.7162 to $55.2802 per EA — the most expensive product costs about 5.2× the cheapest.
Which manufacturers make Rifaximin?
1 manufacturer lists Rifaximin in NADAC. Ranked by number of NDCs, the largest are Salix Pharmaceuticals Inc. (3).